{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:13:00Z","timestamp":1793643180127,"version":"4.5.1"},"reference-count":110,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.mayocp.2021.11.007","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T07:06:20Z","timestamp":1643699180000},"page":"333-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["Diagnosis and Treatment of Acromegaly: An Update"],"prefix":"10.1016","volume":"97","author":[{"given":"Nazanin","family":"Ershadinia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8867-607X","authenticated-orcid":false,"given":"Nicholas A.","family":"Tritos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mayocp.2021.11.007_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A\u00a0Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.mayocp.2021.11.007_bib3","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an Endocrine Society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.mayocp.2021.11.007_bib4","first-page":"717","article-title":"Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human","volume":"19","author":"Giustina","year":"1998","journal-title":"Endocr Rev"},{"issue":"19","key":"10.1016\/j.mayocp.2021.11.007_bib5","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1073\/pnas.1002941107","article-title":"Ghrelin and growth hormone: story in reverse","volume":"107","author":"Nass","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"10.1016\/j.mayocp.2021.11.007_bib6","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1056\/NEJMra1817346","article-title":"Pathogenesis and diagnosis of growth hormone deficiency in adults","volume":"380","author":"Melmed","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5-6","key":"10.1016\/j.mayocp.2021.11.007_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cca.2010.11.008","article-title":"Clinical laboratory indices in the treatment of acromegaly","volume":"412","author":"Clemmons","year":"2011","journal-title":"Clin Chim Acta"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1373\/clinchem.2010.150631","article-title":"Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays","volume":"57","author":"Clemmons","year":"2011","journal-title":"Clin Chem"},{"issue":"6185","key":"10.1016\/j.mayocp.2021.11.007_bib9","doi-asserted-by":"crossref","first-page":"1249783","DOI":"10.1126\/science.1249783","article-title":"Mechanism of activation of protein kinase JAK2 by the growth hormone receptor","volume":"344","author":"Brooks","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.mayocp.2021.11.007_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ghir.2015.09.002","article-title":"Growth hormone signaling pathways","volume":"28","author":"Carter-Su","year":"2016","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib11","doi-asserted-by":"crossref","first-page":"T69","DOI":"10.1530\/JME-17-0311","article-title":"IGF1 receptor signaling pathways","volume":"61","author":"Hakuno","year":"2018","journal-title":"J\u00a0Mol Endocrinol"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jc.2014-2468","article-title":"A\u00a0structural and functional acromegaly classification","volume":"100","author":"Cuevas-Ramos","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","article-title":"The 2017 World Health Organization classification of tumors of the pituitary gland: a summary","volume":"134","author":"Lopes","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.mayocp.2021.11.007_bib14","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2017-02287","article-title":"Genomic alterations and complex subclonal architecture in sporadic GH-secreting pituitary adenomas","volume":"103","author":"Hage","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.mayocp.2021.11.007_bib15","first-page":"1377","article-title":"Genetics of acromegaly and gigantism","volume":"10","author":"Boguslawska","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib16","first-page":"165","article-title":"Acromegaly induced by growth hormone replacement therapy","volume":"61","author":"Karges","year":"2004","journal-title":"Horm Res"},{"issue":"5","key":"10.1016\/j.mayocp.2021.11.007_bib17","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1172\/JCI110708","article-title":"Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor","volume":"70","author":"Thorner","year":"1982","journal-title":"J\u00a0Clin Invest"},{"issue":"25","key":"10.1016\/j.mayocp.2021.11.007_bib18","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1056\/NEJM200006223422504","article-title":"Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma","volume":"342","author":"Beuschlein","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM198501033120103","article-title":"Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor","volume":"312","author":"Melmed","year":"1985","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11102-017-0858-y","article-title":"Silent somatotroph pituitary adenomas: an update","volume":"21","author":"Langlois","year":"2018","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib21","doi-asserted-by":"crossref","first-page":"dgz096","DOI":"10.1210\/clinem\/dgz096","article-title":"A\u00a0consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12020-018-1764-4","article-title":"Signs and symptoms of acromegaly at diagnosis: the physician's and the patient's perspectives in the ACRO-POLIS study [erratum appears in Endocrine. 2019;63(1):130]","volume":"63","author":"Caron","year":"2019","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2265.2009.03626.x","article-title":"Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed","volume":"72","author":"Reid","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.mayocp.2021.11.007_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/EJE-20-0019","article-title":"Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality","volume":"182","author":"Esposito","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.mayocp.2021.11.007_bib25","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/jc.2011-0237","article-title":"A\u00a0novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification","volume":"96","author":"Schneider","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.mayocp.2021.11.007_bib26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ebiom.2017.12.015","article-title":"Automatic detection of acromegaly from facial photographs using machine learning methods","volume":"27","author":"Kong","year":"2018","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11102-017-0849-z","article-title":"Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study","volume":"21","author":"Bonert","year":"2018","journal-title":"Pituitary"},{"issue":"9","key":"10.1016\/j.mayocp.2021.11.007_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043457","article-title":"Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry","volume":"7","author":"Bystrom","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.mayocp.2021.11.007_bib29","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1530\/EC-18-0047","article-title":"Growth Hormone Research Society perspective on biomarkers of GH action in children and adults","volume":"7","author":"Johannsson","year":"2018","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11102-017-0792-z","article-title":"Biochemical investigations in diagnosis and follow up of acromegaly","volume":"20","author":"Schilbach","year":"2017","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.mayocp.2021.11.007_bib31","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1073\/pnas.0337600100","article-title":"Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2","volume":"100","author":"Leung","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1530\/EJE-19-0139","article-title":"Determinants of the growth hormone nadir during oral glucose tolerance test in adults","volume":"181","author":"Schilbach","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-10-0744","article-title":"Limited utility of oral glucose tolerance test in biochemically active acromegaly","volume":"164","author":"Ribeiro-Oliveira","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.mayocp.2021.11.007_bib34","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1210\/jc.2010-0570","article-title":"Acromegaly without imaging evidence of pituitary adenoma","volume":"95","author":"Lonser","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.mayocp.2021.11.007_bib35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1530\/ERC-16-0106","article-title":"Mortality in acromegaly: a 20-year follow-up study","volume":"23","author":"Ritvonen","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.mayocp.2021.11.007_bib36","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1210\/jc.2017-02457","article-title":"Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature","volume":"103","author":"Dal","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A\u00a0meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib39","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1530\/EJE-19-0124","article-title":"Management of endocrine disease: individualised management of acromegaly","volume":"181","author":"Bollerslev","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-020-03669-4","article-title":"Predictors of postoperative biochemical remission in acromegaly","volume":"151","author":"Yao","year":"2021","journal-title":"J\u00a0Neurooncol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-14-0249","article-title":"Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial","volume":"171","author":"Fougner","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.mayocp.2021.11.007_bib42","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1507\/endocrj.K10E-203","article-title":"Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study","volume":"57","author":"Shen","year":"2010","journal-title":"Endocr J"},{"issue":"7","key":"10.1016\/j.mayocp.2021.11.007_bib43","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning\u2013based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.mayocp.2021.11.007_bib44","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s00701-017-3318-6","article-title":"Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications","volume":"159","author":"Chen","year":"2017","journal-title":"Acta Neurochir (Wien)"},{"issue":"3","key":"10.1016\/j.mayocp.2021.11.007_bib45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10143-015-0613-7","article-title":"Endoscopic versus microscopic approach for surgical treatment of acromegaly","volume":"38","author":"Fathalla","year":"2015","journal-title":"Neurosurg Rev"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11102-016-0765-7","article-title":"The surgical treatment of acromegaly","volume":"20","author":"Buchfelder","year":"2017","journal-title":"Pituitary"},{"issue":"10","key":"10.1016\/j.mayocp.2021.11.007_bib47","first-page":"3419","article-title":"Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly","volume":"83","author":"Swearingen","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib48","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/neuros\/nyx020","article-title":"Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors","volume":"81","author":"Babu","year":"2017","journal-title":"Neurosurgery"},{"issue":"6","key":"10.1016\/j.mayocp.2021.11.007_bib49","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1210\/clinem\/dgab069","article-title":"Predictors for remission after transsphenoidal surgery in acromegaly: a Dutch multicenter study","volume":"106","author":"Coopmans","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.mayocp.2021.11.007_bib50","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4158\/EP14587.OR","article-title":"Significant elevation of growth hormone level impacts surgical outcomes in acromegaly","volume":"21","author":"Anthony","year":"2015","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.mayocp.2021.11.007_bib51","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1227\/NEU.0b013e31823f5c16","article-title":"Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly","volume":"70","author":"Kim","year":"2012","journal-title":"Neurosurgery"},{"issue":"5","key":"10.1016\/j.mayocp.2021.11.007_bib52","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11102-020-01063-x","article-title":"Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review","volume":"23","author":"Agrawal","year":"2020","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.mayocp.2021.11.007_bib53","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s11102-017-0832-8","article-title":"Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly","volume":"20","author":"Fahlbusch","year":"2017","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib54","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1530\/EJE-17-0872","article-title":"The comprehensive impact on human body induced by resolution of growth hormone excess","volume":"178","author":"Zhang","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib55","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature","volume":"70","author":"Gunther","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"5","key":"10.1016\/j.mayocp.2021.11.007_bib56","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib57","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.mayocp.2021.11.007_bib58","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.mayocp.2021.11.007_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib60","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11102-019-01020-3","article-title":"Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib61","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.mayocp.2021.11.007_bib62","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11102-019-01023-0","article-title":"MRI texture analysis in acromegaly and its role in predicting response to somatostatin receptor ligands","volume":"23","author":"Galm","year":"2020","journal-title":"Pituitary"},{"issue":"9","key":"10.1016\/j.mayocp.2021.11.007_bib63","first-page":"2768","article-title":"Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients\u2014a clinical research center study [erratum appears in J Clin Endocrinol Metab. 1995;80(11):3238]","volume":"80","author":"Newman","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.mayocp.2021.11.007_bib64","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.mayocp.2021.11.007_bib65","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/ijc.33268","article-title":"miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance","volume":"147","author":"Bogner","year":"2020","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.mayocp.2021.11.007_bib66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/ERC-15-0038","article-title":"X-linked acrogigantism syndrome: clinical profile and therapeutic responses","volume":"22","author":"Beckers","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.mayocp.2021.11.007_bib67","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1210\/jc.2013-3826","article-title":"Acromegaly and McCune-Albright syndrome","volume":"99","author":"Salenave","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.mayocp.2021.11.007_bib68","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s11102-015-0662-5","article-title":"Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis","volume":"18","author":"Efstathiadou","year":"2015","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib69","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.mayocp.2021.11.007_bib70","first-page":"2254","article-title":"An update on pituitary neuroendocrine tumors leading to acromegaly and gigantism","volume":"10","author":"Asa","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"11","key":"10.1016\/j.mayocp.2021.11.007_bib71","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1210\/jc.2005-0998","article-title":"The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly","volume":"90","author":"Bhayana","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib72","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.mayocp.2021.11.007_bib73","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in\u00a0vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.mayocp.2021.11.007_bib74","doi-asserted-by":"crossref","first-page":"L25","DOI":"10.1530\/ERC-12-0020","article-title":"AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression","volume":"19","author":"Kasuki","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.mayocp.2021.11.007_bib75","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-15-0391","article-title":"Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly","volume":"174","author":"Gatto","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.mayocp.2021.11.007_bib76","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1111\/jcmm.13851","article-title":"E-cadherin expression is associated with somatostatin analogue response in acromegaly","volume":"23","author":"Venegas-Moreno","year":"2019","journal-title":"J\u00a0Cell Mol Med"},{"issue":"1-2","key":"10.1016\/j.mayocp.2021.11.007_bib77","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mce.2010.01.033","article-title":"ZAC1 target genes and pituitary tumorigenesis","volume":"326","author":"Theodoropoulou","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"10.1016\/j.mayocp.2021.11.007_bib78","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/ijc.24602","article-title":"Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly","volume":"125","author":"Theodoropoulou","year":"2009","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.mayocp.2021.11.007_bib79","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/0008-5472.CAN-05-1189","article-title":"Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression","volume":"66","author":"Theodoropoulou","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib80","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1210\/jc.2007-2272","article-title":"Low levels of raf kinase inhibitory protein in growth hormone\u2013secreting pituitary adenomas correlate with poor response to octreotide treatment","volume":"93","author":"Fougner","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib81","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib82","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"10.1016\/j.mayocp.2021.11.007_bib83","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib84","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1148\/radiology.213.2.r99nv49317","article-title":"Journey toward computer-aided diagnosis: role of image texture analysis","volume":"213","author":"Tourassi","year":"1999","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.mayocp.2021.11.007_bib85","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.mayocp.2021.11.007_bib86","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib87","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.mayocp.2021.11.007_bib88","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1210\/jc.2018-01524","article-title":"Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression","volume":"104","author":"Muhammad","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.mayocp.2021.11.007_bib89","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.mayocp.2021.11.007_bib90","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib91","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib92","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1210\/clinem\/dgaa882","article-title":"Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints","volume":"106","author":"Stiles","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.mayocp.2021.11.007_bib93","doi-asserted-by":"crossref","first-page":"dgz076","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2021.11.007_bib94","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1530\/eje.0.148s021","article-title":"Discovery and mechanism of action of pegvisomant","volume":"148","author":"Kopchick","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"16","key":"10.1016\/j.mayocp.2021.11.007_bib95","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"9295","key":"10.1016\/j.mayocp.2021.11.007_bib96","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib97","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.mayocp.2021.11.007_bib98","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant","volume":"90","author":"Barkan","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.mayocp.2021.11.007_bib99","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s11102-015-0673-2","article-title":"Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort","volume":"18","author":"Sievers","year":"2015","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/EJE-13-0438","article-title":"Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels [erratum appears in Eur J Endocrinol. 2014;171(6):X5]","volume":"171","author":"Droste","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.mayocp.2021.11.007_bib101","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1210\/jc.2007-1234","article-title":"Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly","volume":"92","author":"Neggers","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib102","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4158\/EP-2019-0528","article-title":"Comparative efficacy of medical treatment for acromegaly: a systematic review and network meta-analysis of integrated randomized trials and observational studies","volume":"26","author":"Qiao","year":"2020","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib103","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1530\/EJE-16-0956","article-title":"A\u00a0multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues","volume":"176","author":"Franck","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.mayocp.2021.11.007_bib104","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.11.007_bib105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrendo.2015.196","article-title":"New therapeutic agents for acromegaly","volume":"12","author":"Melmed","year":"2016","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"10.1016\/j.mayocp.2021.11.007_bib106","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/14656566.2021.1908998","article-title":"New and emerging pharmacological treatment options for acromegaly","volume":"22","author":"Antunes","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.mayocp.2021.11.007_bib107","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1210\/jc.2013-3743","article-title":"Stereotactic radiosurgery for acromegaly","volume":"99","author":"Lee","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib108","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11102-016-0783-5","article-title":"Updates in outcomes of stereotactic radiation therapy in acromegaly","volume":"20","author":"Gheorghiu","year":"2017","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.mayocp.2021.11.007_bib109","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1530\/EJE-19-0784","article-title":"Fractionated radiotherapy and radiosurgery in acromegaly: analysis of 352 patients from the German Acromegaly Registry","volume":"182","author":"Knappe","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.mayocp.2021.11.007_bib110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11154-007-9065-x","article-title":"Radiation therapy in acromegaly","volume":"9","author":"Shih","year":"2008","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619621008454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619621008454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:37:43Z","timestamp":1758418663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619621008454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0025619621008454"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2021.11.007","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Treatment of Acromegaly: An Update","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2021.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}